Phase 4 N=79 Vitamin D Increases Serum Levels of the Soluble Receptor for Advanced Glycation End Products in Women With PCOS
Polycystic Ovary Syndrome · Vitamin D Deficiency
Primary: AMH Levels in Women With PCOS — 1.4; 0 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=184 Symmetric on Total Knee Arthroplasty (TKA)
Wound Closure
Primary: Suturing Time — 15.516; 20.864 minuts
Phase 1 N=58 Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma
Lymphoma, T-Cell, Peripheral · Lymphoma, T-Cell, Cutaneous
Primary: Safety of RP6530 — 0; 0; 0; 2 Participants
N/A N=43 Biomarker and Thrombogenicity Assessment in Cardiopulmonary Bypass Surgery Utilizing Acute Normovolemic Hemodilution
Bleeding Reduction
Primary: Recovery in Platelet Function Post ANH — 2 hours
Phase 4 N=120 Intravenous Dexmedetomidine for Cesarean Section
Breast Feeding · Analgesia Obstetrical · Postoperative Pain
Primary: Postoperative Pain Score (Visual Analogue Scale, VAS) at Rest — 3.143; 2.897; 1.665; 1.25 units on a scale — p=<0.05
N/A N=44 Health Improvement Project - Providence
HIV
Primary: Feasibility of Intervention — 11; 19 Participants
N/A N=261 Comprehensive Shoulder System Nano IDE
Joint Disease
Primary: American Shoulder and Elbow Surgeon's Score (ASES) — 92.20; 92.47 score on a scale
N/A N=334 Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
Rheumatoid Diseases · Rheumatoid Arthritis · Ankylosing Spondylitis
Primary: Treatment Persistence With CT-P13 in Participants With Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PsA) — 404.10; 542.30 days
Phase 2 N=43 Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients
Alzheimer's Disease
Primary: Tolerability and Safety Profile of UB-311 Assessed Via Recording of Number of Participants With Adverse Events — 10; 13; 13 Participants
Phase 2 N=39 Single Agent Regorafenib in Refractory Advanced Biliary Cancers
Cancer of the Bile Duct
Primary: Overall Survival (OS) at 6 Months — 7.9 months
Phase 2 N=9 Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Pituitary Adenomas · Prolactinomas
Primary: Change in Tumor Volume — 10 Percent volume
N/A N=11 TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma
Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…
Phase 2 N=297 Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
Relapsing-remitting Multiple Sclerosis
Primary: Dose Responsiveness of BAF312 Based on the Number of Combined Unique Active MRI Lesions (CUAL) — 0.51; 0.83; 7.46 mg
N/A N=289 Comparative Effectiveness Trail to Reduce Child Maltreatment, Improve Client Outcomes and Examine Client Burden
Child Maltreatment
Primary: Parenting Young Children Scale-Supporting Positive Behavior Sub-scale — 6.14; 6.29; 6.43; 6.29 units on a scale — p=0.12
Phase 2 N=115 S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
Leukemia
Primary: Complete Remission (CR) Rate (Including CR With Incomplete Recovery) — 27; 14; 14 Participants